Lupin gets inspection closure report from USFDA for Pithampur plant

The US Food and Drug Administration (USFDA) has closed its inspection of Lupin's manufacturing facility in Pithampur, Madhya Pradesh, the company said on Thursday.

The inspection for the facility was conducted by the US health regulator between February 3 and February 11, 2020, and concluded with two observations, the Mumbai-based company said.

The company has received the establishment inspection report (EIR) from USFDA for its Pithampur Unit-1 facility, Lupin said.

The USFDA issues an EIR to a company when an inspection is satisfactorily closed.
Lupin Managing Director Nilesh Gupta, said the company has received the EIR for the plant with Voluntary Action Indicated (VAI) status.

"Continuous improvement of our quality and compliance standards across all our manufacturing sites is a key focus area for the company and we are committed to working with the USFDA to manufacture and supply products of the highest quality from all our manufacturing sites," he added.

On Wednesday, the company announced that it received tentative approval for its Arformoterol Tartrate Inhalation Solution from the US drug regulator. The solution is indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD).

Following the development, Lupin shares gained 1.62% to Rs 868.10 before falling to Rs 823.

Biocon receives EIR from USFDA for good manufacturing practice inspection

Currrent Affairs
Biocon on Friday said it has gotten the foundation review report (EIR) from US wellbeing controller for the post-endorsement and great assembling practice (GMP) investigation of its little particles fabricating office in Bengaluru.
"The EIR has been shut with a willful activity demonstrated (VAI) arrangement for the perceptions, the organization representative said in a recording to BSE.
"Biocon has gotten the EIR from the US Food and Drug Administration (FDA) for the post-endorsement and GMP assessment of its little atoms dynamic pharmaceutical fixing (API) fabricating office at twentieth KM, Biocon Campus, Bengaluru, directed between Feb 20 and Feb 26, 2020," according to the recording.
At the finish of the review a month ago, the organization had given a Form 483, with two perceptions, which were procedural in nature and are being tended to by the organization, the documenting said.
"We stay focused on worldwide guidelines of value and consistence," organization representative included.

The portions of Biocon were exchanging at Rs 257.00 each on the BSE, up 1.76 from the past close.